They met their EBITDA guidance. Huge amount of abnormals...

They met their EBITDA guidance. Huge amount of abnormals impacting profit. Anyone who thought there was going to be any result different to this was living in la la land. EBITDA improving next year, they have said the abnormals are finished. Maybe maybe not - we will see in February. Carminosca legal problems still hanging over. I think it is a turnaround, although I wouldn't be buying into it, if I wasn't kind of committed already. Overvalued currently? Probably but I think the market is looking forward and believing in the turnaround story (and continuing buybacks). Will it stay at this price? Possibly not - carry on bouncing in a band between 1.15 and 1.25.